nejm.org

Root domain: nejm.org The root domain (apex) without subdomains 11423 days old

Registration Date

October 08, 1994

11423 days ago

Updated 13 days ago

clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited

Domain Status

clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited

Expires

October 07, 2026

in 9 months

ns-1284.awsdns-32.org +3

Nameservers

ns-1284.awsdns-32.org

ns-1559.awsdns-02.co.uk

ns-165.awsdns-20.com

ns-928.awsdns-52.net

Updated 13 days ago

Keywords

Currently ranking

Unique keywords

High value

> $100 / month

Estimated Traffic

How is this calculated?

Estimated traffic is calculated using:

Search Volume × CTR (by position)

CTR varies by position:

Monthly visits

Across all rankings

Traffic value

—

Estimated monthly

Activity

Last seen

Jan 06

10 days ago

First seen

Jan 03, 2026

13 days ago

Keyword rankings

Showing 1-2 of 2 rankings

Show:

Keyword / Page	Position	Estimated Traffic How is this calculated? Estimated traffic is calculated using: Search Volume × CTR (by position) CTR varies by position: Position 1: 30% Position 2: 15% Position 3: 10% Positions 4-10: Decreasing rates Position 11+: 0.5%	Estimated Traffic Value How is this calculated? Estimated traffic value is calculated using: Estimated Traffic × CPC This represents the estimated monthly value of the traffic based on the keyword's cost-per-click (CPC) from Google Ads data.	Last Seen	Actions
wearables in healthcare Wearable Digital Health Technology /doi/full/10.1056/NEJMe2303219	4 Best: 4 • Worst: 4	1 visits/month	—	13 days ago	Search Profile 🇸🇪 Sweden Mobile Wearable Digital Health Technology /doi/full/10.1056/NEJMe2303219 av SH Friend · 2023 · Citerat av 77 — “Wearables” is a term used for forms of technology that are worn on the body, such as smartwatches or adhesive patches containing sensors, and ...
gad test diabetes GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes /doi/full/10.1056/NEJMoa0804328	7 Best: 7 • Worst: 7	—	—	10 days ago	Search Profile 🇸🇪 Sweden Mobile GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes /doi/full/10.1056/NEJMoa0804328 av J Ludvigsson · 2008 · Citerat av 648 — This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age.